ORIC Pharmaceuticals

Update in progress

ORIC (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

ORIC Pharmaceuticals is a clinical-stage biopharma focused on therapies to overcome cancer resistance mechanisms. Its candidates include enozertinib (ORIC-114), a brain-penetrant, orally bioavailable irreversible EGFR inhibitor targeting EGFR exon 20 and exon 20 insertions, in Phase 1b; and rinzimetostat (ORIC-944), an allosteric EZH2/PRC2 inhibitor for prostate cancer in Phase 1b. It has collaboration agreements with Bayer and Johnson & Johnson. Founded in 2014, based in South San Francisco.

Company score

Sentiment: 0.14; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.07; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.06; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive